Coronavirus

Intensive care medicine

2019-20 coronavirus outbreak

Virology

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Outbreak

Coronavirus disease 2019 (COVID-19)

Immunology

Respiratory failure

Infectious disease (medical specialty)

Internal medicine

Dexamethasone

Medicine

Disease

Myasthenia gravis

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

Myasthenia gravis and the associated pharmacologic management options could place patients at higher risk of contracting severe acute respiratory syndrome coronavirus 2 and exhibiting more severe manifestations of the novel coronavirus disease 2019 (COVID‐19). Multiple agents have been studied for the management of the COVID‐19, including remdesivir. To date, no published reports have evaluated the utilization of the antiviral remdesivir in patients with myasthenia gravis. We describe the first reported clinical course of three patients with myasthenia gravis who safely received remdesivir in combination with dexamethasone for the management of COVID‐19.

Use of Remdesivir in Myasthenia gravis and COVID‐19